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Antioxidant treatment enhances 
human mesenchymal stem cell 
anti-stress ability and therapeutic 
efficacy in an acute liver failure 
model
Wen Zeng1,2,*, Jia Xiao1,3,4,*, Gang Zheng2, Feiyue Xing3, George L. Tipoe4, Xiaogang Wang3, 
Chengyi He2, Zhi-Ying Chen2 & Yingxia Liu1
One of the major problems influencing the therapeutic efficacy of stem cell therapy is the poor cell 
survival following transplantation. This is partly attributed to insufficient resistance of transplanted 
stem cells to oxidative and inflammatory stresses at the injured sites. In the current study, we 
demonstrated the pivotal role of antioxidant levels in human umbilical cord mesenchymal stem cells 
(hUCMSCs) dynamic in vitro anti-stress abilities against lipopolysaccharide (LPS)/H2O2 intoxication 
and in vivo therapeutic efficacy in a murine acute liver failure model induced by D-galactosamine/
LPS (Gal/LPS) by either reducing the antioxidant levels with diethyl maleate (DEM) or increasing 
antioxidant levels with edaravone. Both the anti- and pro-oxidant treatments dramatically influenced 
the survival, apoptosis, and reactive oxygen species (ROS) production of hUCMSCs through 
the MAPK-PKC-Nrf2 pathway in vitro. When compared with untreated and DEM-treated cells, 
edaravone-treated hUCMSCs rescued NOD/SCID mice from Gal/LPS-induced death, significantly 
improved hepatic functions and promoted host liver regeneration. These effects were probably from 
increased stem cell homing, promoted proliferation, decreased apoptosis and enhanced secretion 
of hepatocyte growth factor (HGF) under hepatic stress environment. In conclusion, elevating levels 
of antioxidants in hUCMSCs with edaravone can significantly influence their hepatic tissue repair 
capacity.
In clinic, for the therapy of acute and chronic end-stage liver diseases, including acute liver failure, cir-
rhosis and liver cancer, transplantation is the gold standard procedure. However, severe global shortage 
of donor organs and possible immunological rejection significantly restrict its wide application1. Among 
various alternative therapeutic strategies, replacing damaged host hepatocytes and stimulating endog-
enous liver regenerative processes with transplanted stem cells hold promising prospect2,3. Currently, 
successful disease improvements by stem cell therapy have been achieved in drug-induced liver injury4, 
acute liver failure5, alcoholic liver disorders6, non-alcoholic fatty liver disease7, and liver fibrosis8. For the 
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treatment of liver cancer, there are only a limited number of trials that used stem cells to treat hepato-
cellular carcinoma (HCC) and the results are quite controversial9.
Although stem cell therapy in the liver exhibits a variety of advantages such as pluripotency, 
self-renewal, ease of harvest, and minimal immunogenicity, in both pre-clinical studies and clinical tri-
als, poor cell survival following transplantation continues to limit the efficacy of this therapy10,11. This is 
predominantly attributed to the inflammatory and oxidative stress environment at the site of injury12. It 
has been proposed that endogenous antioxidant level of stem cells could influence their fate after trans-
plantation at injured host sites. For example, endothelial progenitor cells are shown to express high level 
of antioxidant enzymes and to have increased abilities of DNA repair as compared to more differentiated 
endothelial cells. Therefore, they are less sensitive to oxidative stress–induced apoptosis13. Similarly, after 
treatment with antioxidant N-acetylcysteine, muscle-derived stem cells (MDSCs) showed increased sur-
vival ratio and better ameliorative effects on an acute murine model of myocardial infarction14. However, 
information regarding the dynamic effects and mechanisms of stem cell endogenous antioxidant level 
on their anti-stress ability against exogenous stresses, particularly on liver disease is lacking. Moreover, 
the in vitro treatment agent, dose, and time-window are extremely important determinants influenc-
ing in vivo transplantation. In this study, we tested treatment time-windows of antioxidant edaravone 
and pro-oxidant diethyl maleate (DEM) in human umbilical cord mesenchymal stem cells (hUCMSCs) 
against lipopolysaccharide (LPS)/H2O2 challenge. The ameliorative effects and mechanisms of edaravone- 
or DEM-treated hUCMSCs on a murine acute liver failure model were then examined.
Methods
Reagents and antibodies. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) was purchased 
from Mitsubishi Pharma Corporation (Tokyo, Japan). DEM, D-galactosamine (Gal), LPS, and 
methylthiazolyldiphenyl-tetrazolium bromide (MTT) were products from Sigma-Aldrich (St Louis, 
MO). PD98059 and staurosporine were products of Calbiochem (Billerica, MA). All cell culture consum-
ables and reagents were bought from either Corning Incorporated (Corning, NY) or Gibco (Carlsbad, 
CA). Antibodies against catalase (CAT), SOD1, phosphorylated p38 MAPK at Thr180/Tyr182, total p38 
MAPK, phosphorylated ERK at Thr202/Tyr204, total ERK, and β -actin were bought from Cell Signaling 
(Beverly, MA).
Isolation and expansion of hUCMSCs. Procedures for hUCMSCs isolation and expansion were 
performed as previously described15. All clinical procedures followed the protocols approved by the eth-
ical committee of Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences. All partic-
ipants provided their written consents for the current study.
Cellular treatments. hUCMSCs from passages 2 were seeded in 24-well plates with confluence 
around 60%–70% before treatment in a regulator cell CO2 incubator. Cells were divided into 5 groups 
(n = 4): (1) control group: no additional treatment; (2) oxidative/inflammatory stress (LPS) group: cells 
were treated with 0.1 μ g/ml LPS and 200 μ M H2O2 simultaneously; (3) LPS+ Eda10 group: 2 hours before 
LPS/H2O2 treatment, cells were pre-incubated with 10 μ M edaravone; (4) LPS+ Eda20 group: 2 hours 
before LPS/H2O2 treatment, cells were pre-incubated with 20 μ M edaravone; (5) LPS+ DEM group: 
2 hours before LPS/H2O2 treatment, cells were pre-incubated with 50 μ M DEM. To delineate the optimal 
treating combination of dosage and duration, we collected treated cells at 12, 24, 36, 48, 60, and 72 hours 
post-treatment. It should be noted that 200 μ M H2O2 is a relatively high concentration compared to levels 
observed in vivo during inflammation (~5 μ M). We used this concentration in the current study to com-
pensate for the lack of other reactive oxygen species (ROS) and pro-inflammatory cytokines observed 
in injured host tissues14.
MTT assay. Cell viability was evaluated by the conversion of MTT to a purple color product by 
cellular mitochondria. After drug treatment, cells from each group were washed by sterile PBS 3 times 
and then incubated with 5 mg/ml MTT for 3 hours, and subsequently dissolved in dimethyl sulfoxide 
(DMSO). The absorbance of MTT was measured at 570 nm.
Apoptotic ratio measurements. After drug treatment, Hoechst 33342 (5 μ g/ml) and propidium 
iodide (5 μ g/ml) were added to each well to stain live cells. The results were expressed as the percentage 
of apoptosis (PA): PA = apoptotic cell number/ total cell number × 100%16.
Caspase-3/7 activity measurements. Activities of caspases-3/7 from cell lysates after treatments 
were measured using Cell Meter Caspase 3/7 Activity Apoptosis Assay Kit (AAT Bio., Sunnyvale, CA) 
according to the user manual. Final results were read at 520 nm in a micro-plate reader (Bio-Rad) and 
expressed as fold change in caspase 3/7 activity from control.
ROS staining. Intracellular production of ROS was detected by fluorescence probe 2’,7’-dichloro 
-fluorescin diacetate (DCFH-DA, Sigma-Aldrich) as previously described17. Briefly, after treatment, cells 
were washed three times with PBS and then incubated in 10 μ M DCFH-DA for 30 min at 37 °C for 
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green fluorescent light visualization. Quantification of green fluorescence was analyzed by using ImageJ 
(Version 1.48, National Institutes of Health, Bethesda, MD).
RNA extraction and quantitative PCR assay. Total RNA of cells was extracted by using illustraTM 
RNAspin mini kit (GE healthcare, UK). The preparation of the first-strand cDNA was conducted fol-
lowing the instruction of the SuperScriptTM First-Strand Synthesis System (Invitrogen, Calsbad, CA). 
The mRNA expression levels of Bcl-2, Bax1, NAD(P)H:quinone oxidoreductase-1 (NQO-1), malic 
enzyme-1 (ME-1), oncostatin M (OSM) and epidermal growth factor (EGF) (for sequence information, 
see Supplementary Table 1) were measured by Takara SYBR premix Taq quantitative PCR system (Takara 
Bio Inc, Shiga, Japan) and in MyiQ2 real-time PCR machine (Bio-Rad, Hercules, CA). Parallel amplifica-
tion of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal control. Relative 
quantification was done by using the 2−ΔΔCt method. The relative expression of the specific gene to the 
internal control was obtained and then expressed as percentage of the control value. All real-time PCR 
procedures including the design of primers, validation of PCR environment and quantification methods 
were performed according the MIQE guideline18.
Cellular protein extraction, Western blotting, and Nrf2 activity assay. At each treatment 
time-point, cells were washed with sterile PBS for 3 times and then subjected to cytosolic and nuclear 
protein extraction by using a NE-PER Nuclear and Cytoplasmic Extraction System (Pierce, Rockford, 
IL). Protein samples were then quantified with BCA method from Bio-Rad. Western blot analyses of 
cell lysates were performed as described19. Parallel blotting of β -actin was used as the internal control.
To further investigate the mechanism of endogenous antioxidant level change, the nuclear protein 
of each sample was subjected to the measurement of Nrf2 transcription factor activity assay by using a 
commercial kit from Cayman Chemical Company (Ann Arbor, MI).
GSH/GSSG ratio measurements. To measure the intracellular oxidative status of stem cells, the 
ratio between reduced glutathione (GSH) to oxidized glutathione (GSSG) of each cellular protein sample 
was measured by using a GSH/GSSG detection assay kit from Abcam (Cambridge, England).
Inhibition of the ERK, PKC, and Keap1 pathways. To further investigate the underlying mech-
anisms contributing to the endogenous antioxidant level of hUCMSCs after edaravone or DEM 
pre-treatment, we firstly transiently silenced the expression of Keap1, the repressor of Nrf2 activation 
using its specific siRNA combination (Santa Cruz BioTechnology, Santa Cruz, CA). Transfection of 
Keap1 siRNA (100 nM) was conducted 1-day before the pre-treatment with DEM by using Lipofectamine 
3000 (Invitrogen, Carlsbad, CA). Given the function of the ERK and PKC pathway in oxidative stress 
progression, the role of ERK/MAPK or PKC signaling following edaravone treatment was evaluated. That 
is, 1-hour before the edaravone (20 μ M) incubation, cells were treated with 25 μ M PD98059 (specific 
ERK/MAPK inhibitor) or 10 nM staurosporine (specific PKC inhibitor). Then cells were subjected to 
LPS/H2O2 challenge as previously described.
Animal experiments. All animal experiments, including procedures, sampling and animal cares, in 
the current study were approved by and in accordance with guidelines and regulations from the ethical 
committee of Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences. Male 6-week 
old (~20 g) non-obese diabetic severe combined immune-deficient (NOD/SCID) mice were bought 
from Guangdong Experimental Animal Center (Guangzhou, China). Mice were randomly divided into 
8 groups (n = 12): (1) control group: mice were intraperitoneally (i.p.) injected with PBS only; (2) Gal/
LPS group: mice were i.p. injected with 600 mg/kg Gal and 8 μ g/kg LPS dissolved in PBS simultane-
ously; (3–5) vehicle-stem cell groups: mice were injected through tail-vein (t.v.) with 2 × 106 hUCMSCs 
(untreated, 20 μ M edaravone-pretreated, and 50 μ M DEM-pretreated, respectively) at passage 2; (6–8) 
Gal/LPS-stem cell groups: mice received 600 mg/kg Gal and 8 μ g/kg LPS via i.p. injection, followed 
6-hour later by 2 × 106 hUCMSCs (untreated, 20 μ M edaravone-pretreated, and 50 μ M DEM-pretreated, 
respectively) at passage 2 through t.v. injection. The dosage combination of Gal and LPS, as well as the 
delivery route of stem cells were selected based on our previous study20. Murine serum was collected at 
day 1, 3, and 7 post-transplantation. Liver samples were collected at the end of the 7-day experiment and 
stored at –80 °C until further processing.
Serum and liver tissue analysis. Serum was collected by centrifugation from whole blood sample at 
1,000 xg for 10 min at 4 °C and stored at –80 °C. Liver tissue samples were fixed in 10% phosphate-buffered 
formalin, processed for histology and embedded in paraffin blocks. Five-micrometer tissue sections were 
cut and stained with hematoxylin and eosin (H&E).
Serum ALT and AST assay. To evaluate the hepatic injury at the enzymatic level, serum ALT and 
AST levels were measured by using ALT (SGPT) and AST (SGOT) reagent sets (Teco diagnostics, 
Anaheim, CA) according to manufacturer’s instructions.
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Genomic DNA extraction and quantitative real-time PCR. To quantify the transplanted hUCM-
SCs and i-Heps that homed at the mice liver, a recently established real-time PCR quantification system 
has been used in the current study21. Briefly, genomic DNA at day 7 post-treatment was extracted from 
mouse livers using QIAamp genomic DNA extraction kit (Qiagen, Hilden, Germany). A pair of primers 
(see Supplementary Table 1 for sequence information) that generate a 141-bp fragment of human Down 
syndrome region at chromosome 21 were used to quantify the human-derived cells. The real-time PCR 
reaction was performed using an ABI 7500 real-time PCR system (Applied Biosystems, Foster City, 
CA) for 40 cycles with denaturing at 95 °C for 30 seconds and annealing at 63 °C for 34 seconds, with a 
SYBR-Green Realtime PCR mix (Takara, Dalian, China).
PKH labeling and fluorescent microscopy. The fluorescent dye PKH26 has been used as the cell 
tracer to locate the transplanted stem cells in host animal22. Before transplantation, hUCMSCs at passage 
2 were labeled with the PKH26 MINI kit (Sigma-Aldrich) according to the manufacture’s suggestions 
and previously reported protocol23. When animals were sacrificed, liver tissues were cryopreserved in 
optimal cutting temperature medium (OCT, TissueTek, SakuraAmericas, Torrence, CA). Frozen tissue 
sections (5 μ m) were collected on glass slides and fixed with 100% methanol for 10 min at 4 °C, then 
washed in PBS for 10 min at room temperature. Local hepatic cells were mounted using DAPI mounting 
solution (Beyotime Biotechnology, Jiangsu, China) and used to normalize the expansion percentage of 
transplanted stem cells.
hUCMSCs proliferation and apoptosis following transplantation. After 7-day post-transplantation 
to the injured NOD/SCID mice liver, donor hUCMSCs proliferation was quantified by immunohisto-
chemical staining of PCNA. Fresh liver tissues were embedded with OCT medium and “snap-frozen” in 
dry ice. Frozen sections of 10-μ m thickness were prepared and subjected to permeabilization in acetone 
at –20 °C for 10 min. To reduce non-specific signal, slides were incubated with goat serum blocking 
buffer (Boster, Wuhan, China) at room temperature for 1-hour. Subsequently, the slides were incubated 
with primary antibodies PCNA (1:100, Cell Signaling). After washing thrice with PBS, slides were incu-
bated with mouse antibody against mouse IgG conjugated with Alexa flour (1:1000, Cell Signaling). 
Sections were co-stained with human cytokeratin-18 (hCK-18; 1:100, Abcam HK, NT, HK) and goat 
antibody against rabbit IgG conjugated with FITC (1:1000, Abcam HK). Apoptosis was quantified by 
terminal dUPT nick end-labeling (TUNEL) using ApopTag Plus Peroxidase In Situ Apoptosis Detection 
Kit (Chemicon, Billerica, MA) after 3-day post-transplantation. The number of PCNA cells or apoptotic 
cells was quantified in 3 microscopic fields at × 40 magnification using ImageJ software.
Serum ELISA assay. Serum level of TNF-α and IL-6 from each mouse was measured by using ELISA 
kits from PeproTech (Rocky Hill, NJ) according to the manufacturer’s instructions.
In vitro and in vivo secretion of hepatocyte growth factor (HGF) by hUCMSCs. For the evalu-
ation of HGF secretion by hUCMSCs in vitro, cells at passage 3 were received pre-treatment with edara-
vone or DEM as described above and then washed thrice with Ca2+ and Mg2+-free PBS (Sigma-Aldrich), 
and cultured in 10 ml DMEM supplemented with 0.05% bovine serum albumin (BSA, Sigma-Aldrich) 
for 24 hours. After that, collected and concentrated conditioned medium was subjected to HGF ELISA 
measurement (RayBioteck, Norcross, GA). For in vivo measurements, paraffin embedded liver tissues at 
day 7 post-challenge were prepared for immunohistochemical staining of HGF. HGF-secreting cells were 
labeled with HRP/DAB system (Zhongqiao, Beijing, China). Hematoxylin was used as the counterstain 
of cellular nuclei.
Statistical analysis. Data from each group were expressed as means ± SEM. Statistical comparison 
between groups was done using the Kruskal–Wallis test followed by Dunn’s post hoc test to detect differ-
ences in all groups. A value of p < 0.05 was considered to be statistically significant (Prism 5.0, Graphpad 
software, Inc., San Diego, CA).
Results
Edaravone improved hUCMSCs viability and morphology after oxidative/inflammatory chal-
lenge. Similar to the in vivo situation, potent oxidative/inflammatory stress in vitro (LPS/H2O2 incu-
bation) caused evident decrease of cell viability, particularly after 24 hours of the challenge (P < 0.05; 
Fig. 1A). Pre-treatment with pro-oxidant DEM further reduced the viability of stem cells challenged by 
LPS/H2O2 at all time-points post-treatment (P < 0.05). As expected, both concentration of edaravone 
significantly recovered the cell viability impaired by the challenge of LPS/H2O2 (P < 0.05; Fig. 1A). There 
was no significant change of cell viability between 10 μ M and 20 μ M edaravone pre-treated hUCMSCs 
(P > 0.05). In consistent with the viability results, LPS/H2O2 challenge resulted in obvious morphological 
change of hUCMSCs, including cell shrinkage and occurrence of apoptosis (Fig. 1B). Pre-treatment with 
DEM significantly increased the number of abnormal cells, while edaravone recovered the cell morphol-
ogy (Fig. 1B).
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Figure 1. In vitro dynamic effects of edaravone and diethyl maleate (DEM) treatments of human 
umbilical cord mesenchymal stem cells (hUCMSCs) on cell viability and morphology after 
lipopolysaccharide (LPS)/H2O2 intoxication (n = 4). (a) Edaravone treatment significantly increased the 
cell viability damaged by LPS/H2O2 challenge. DEM treatment exacerbated the cell viability. “*” means 
significant changes (P < 0.05) between control and treatments; “#” means significant changes (P < 0.05) 
between edaravone treatment groups (10 μ M and 20 μ M) and LPS/H2O2 group; “@” means significant 
change (P < 0.05) between DEM-treated group and LPS/H2O2 group. (b) Edaravone improved hUCMSCs 
cell morphology damaged by LPS/H2O2 challenge while DEM further exacerbated it. Arrows indicate 
typical abnormal hUCMSCs. LPS, LPS/H2O2 challenge; Eda10, 10 μ M edaravone; Eda20, 20 μ M edaravone. 
Magnification 200x (Magnified part 400x).
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Increased endogenous antioxidant level attenuated stem cell apoptosis. To investigate the 
effects and mechanisms of endogenous antioxidant level on the pathogenesis of apoptosis under oxida-
tive/inflammatory stress, the apoptotic ratio and corresponding caspase-3/7 activity were examined at 
each time point after LPS/H2O2 challenge. It was shown that the basal apoptotic ratio slightly increased 
from the beginning of the experiment to 72-hour post-treatment (~2.0% vs. ~3.6%, P < 0.05). LPS/H2O2 
challenge significantly increased the cellular apoptosis as time prolonging (P < 0.001). Pre-treatment 
with edaravone (10 μ M and 20 μ M) or DEM significantly decreased or further increased the apoptosis 
of hUCMSCs, respectively (P < 0.05 or < 0.001; Fig. 2A). The activity change of cellular caspase-3/7 was 
consistent with the change of cellular apoptotic ratio (Fig. 2B). To confirm the involvement of intrinsic 
apoptotic pathway in this study, the mRNA expressional changes of Bcl-2 and Bax1 were then quantified 
by quantitative PCR. Results exhibited that, when compared with the control group, LPS/H2O2 challenge 
significantly down-regulated the mRNA level of anti-apoptotic molecule Bcl-2, while up-regulated the 
mRNA level of pro-apoptotic molecule Bax1 at 12, 24, 36, 48, 60, 72-hour post-treatment. Pre-treatment 
with both concentrations of edaravone abolished such effects. DEM pre-incubation further reduced the 
level of Bcl-2 and increased the level of Bax1 after LPS/H2O2 challenge, indicating an exacerbated status 
of stem cell apoptosis (Fig. 2C,D).
Edaravone attenuated cellular ROS production after oxidative/inflammatory challenge. To 
directly demonstrate the antioxidant effects of edaravone on LPS/H2O2-caused oxidative stress, 
DCFH-DA staining of hUCMSCs was applied to show the change of cellular ROS production. From 
24-hour post-treatment afterwards, LPS/H2O2-induced obvious DCFH-DA positive signals in the cul-
ture medium, which was attenuated by edaravone pre-treatment but worsened by DEM pre-treatment 
(Fig. 3A,B). In cells, a decreased ratio of GSH/GSSG is an indication of oxidative stress, since when cells 
are exposed to increased levels of oxidative stress, oxidized glutathione (GSSG) accumulates and the 
reduced form (GSH) decreases24. In line with the ROS production, LPS/H2O2 challenge caused signifi-
cant decrease of cellular GSH/GSSG ratio when compared with that of the control group at 12, 24, 36, 
48, 60, and 72 hours post-treatment. Such decreases were evidently restored by edaravone (10 μ M and 
20 μ M) but further reduced by DEM (Fig. 3C). It should be noted that the restoration of GSH/GSSG by 
Figure 2. In vitro dynamic effects of edaravone and diethyl maleate (DEM) treatments of human 
umbilical cord mesenchymal stem cells (hUCMSCs) on cell apoptosis after lipopolysaccharide (LPS)/
H2O2 intoxication (n = 4). (a) Apoptotic ratio, (b) caspase-3/7 activity, (c) cellular Bcl-2 mRNA expression 
and (d) cellular Bax1 mRNA expression of each group of hUCMSCs after different durations of LPS/H2O2 
challenge. LPS, LPS/H2O2 challenge; Eda10, 10 μ M edaravone; Eda20, 20 μ M edaravone. “**” means P < 0.01 
against control group; “***” means P < 0.001 against control group; “#” means P < 0.05 against LPS/H2O2 
group; “##” means P < 0.01 against LPS/H2O2 group; “###” means P < 0.001 against LPS/H2O2 group.
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Figure 3. In vitro dynamic effects of edaravone and diethyl maleate (DEM) treatments of human 
umbilical cord mesenchymal stem cells (hUCMSCs) on reactive oxygen species (ROS) production and 
GSH/GSSG ratio change after lipopolysaccharide (LPS)/H2O2 intoxication (n = 4). (a) The production of 
ROS was stained by DCFH-DA of each group of hUCMSCs after different durations of LPS/H2O2 challenge. 
(b) Quantification of ROS production. (c) Cellular GSH/GSSG change of each group of hUCMSCs was 
examined by commercial kit. LPS, LPS/H2O2 challenge; Eda10, 10 μ M edaravone; Eda20, 20 μ M edaravone. 
Magnification 200x. “**” means P < 0.01 against control group; “***” means P < 0.001 against control group; 
“#” means P < 0.05 against LPS/H2O2 group; “##” means P < 0.01 against LPS/H2O2 group; “###” means 
P < 0.001 against LPS/H2O2 group.
www.nature.com/scientificreports/
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edaravone is incomplete and appeared to be deteriorated at longer time points of 60 and 72 h, probably 
due to the decreased and desensitized endogenous antioxidant pathway of stem cells in response to 
exogenous antioxidant stimulation, which needs further investigation.
Edaravone restored levels of endogenous antioxidant enzymes impaired by oxidative/inflam-
matory challenge. CAT and SOD1 are important endogenous antioxidant enzymes against intra-
cellular and extracellular oxidative stress25. Western blotting results suggested that at 12, 24, 36, 48, 60, 
and 72 hours after LPS/H2O2 treatment, the protein expression levels of both CAT and SOD1 were sig-
nificantly down-regulated (particularly for SOD1; Fig. 4). Edaravone pre-treatment significantly restored 
Figure 4. In vitro dynamic effects of edaravone and diethyl maleate (DEM) treatments of human 
umbilical cord mesenchymal stem cells (hUCMSCs) on antioxidant enzymes (catalase, CAT and 
superoxide dismutase-1, SOD1) expression after lipopolysaccharide (LPS)/H2O2 intoxication (n = 4). The 
protein expression of both CAT and SOD1 was measured by Western blot (a) and normalized by internal 
control β -actin (b). Quantified data were conducted by using ImageJ. LPS, LPS/H2O2 challenge; L+ E10, 
LPS/H2O2 + 10 μ M edaravone; L+ E20, LPS/H2O2 + 20 μ M edaravone; L+ D, LPS/H2O2 + DEM. “*” “**” “***” 
mean significant changes (P < 0.05, 0.01, 0.001) between control and treatments, respectively; “#” “##” “###” 
mean significant changes (P < 0.05, 0.01, 0.001) between edaravone treatment group (10 μ M or 20 μ M) and 
LPS/H2O2 group, respectively; “@” “@@” “@@@” mean significant change (P < 0.05, 0.01, 0.001) between 
DEM-treated group and LPS/H2O2 group, respectively.
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their expression levels while DEM pre-incubation reduced them to lower levels (P < 0.05; Fig. 4), indicat-
ing that the redox regulating effects of edaravone and DEM were directly associated with the modulation 
of endogenous antioxidant enzymes.
Edaravone and DEM influence stem cell antioxidant level through regulating MAPK, PKC 
and Nrf2 pathways. Under oxidative stress, MAPK and PKC pathways are activated to degrade 
Keap1, the repressor of transcription factor Nrf2, leading to the activation of Nrf2 and downstream 
antioxidant processes in the cell26. To test the involvement of these mechanisms in the antioxidant sta-
tus change of hUCMSCs, we firstly measured the change of the MAPK pathway. Results showed that 
LPS/H2O2 treatment potentiated the phosphorylation of both p38 MAPK and ERK1/2 at most time 
points post-treatment without influencing their total protein expression (Fig. 5). In agreement with pre-
vious results, pre-treatment with edaravone or DEM significantly abolished or further strengthened the 
effects of LPS/H2O2 treatment, respectively (Fig. 5). Then the transcriptional activity change of Nrf2 was 
assessed. It was found that at 12, 24, 36, 48, 60, and 72 hours after LPS/H2O2 treatment, the activity of 
Nrf2 was significantly decreased when compared with the control group (Fig. 6A). Application of 20 μ M, 
but not 10 μ M edaravone partially restored the activity. Pre-incubation with DEM, as expected, further 
reduced the activity of Nrf2 (Fig. 6A). In addition, the mRNA expression of Nrf2 downstream antioxi-
dant genes, NQO-1 and ME-1 was also down-regulated by LPS/H2O2 challenge at most of the treatment 
time points, which was in agreement with the results of CAT/SOD1 protein expression. Edaravone and 
DEM further differentiately regulated their expressions (Fig. 6B,C). Under oxidative/inflammatory stress 
conditions (LPS/H2O2 exposure), the inhibition of the ERK or PKC pathway, using PD98059 or stauro-
sporine, respectively, caused a significant decrease in the cell survival of edaravone-treated hUCMSCs 
compared to uninhibited edaravone-treated hUCMSCs (Fig.  6D). Vehicle-PD98059 or staurosporine 
treatment in hUCMSCs only slightly reduced their survival rates when compared to rates of uninhibited, 
hUCMSCs, indicating that the decrease of cell viability was not attributed to the a direct toxicity of these 
agents (data not shown). Then we examined the effects of Keap1 silence (which causes the enhancement 
of Nrf2 activity) on DEM-treated hUCMSCs. Twenty four hours after the Keap1 siRNA transfection, the 
activity of Nrf2 in hUCMSCs was significantly higher than that of un-transfected or transfected with 
control siRNA cells (P < 0.001; Fig. 6E). After the LPS/H2O2 exposure, the inhibition of Keap1 partially 
restored the cell viability that impaired by the pre-incubation with DEM (Fig. 6F), indicating an essential 
involvement of Nrf2 in the antioxidant properties of hUCMSCs.
In vivo hUCMSCs engraftment and survival in an acute liver injury model. Seven days after 
the Gal/LPS intoxication of NOD/SCID mice, 50% of mice tested (n = 12) survived. For those mice 
with co-injection of hUCMSCs, only 2 mice were dead. Edaravone-pretreatment successfully rescued 
all mice. In the group of DEM-pretreated prior to Gal/LPS intoxication, however, 3 mice died during 
the experiment (Fig. 7A). Gal/LPS treatment is known to induce hepatocyte necrosis and inflammatory 
responses. In the current study, Gal/LPS treatment alone caused evident hepatic necrosis in the NOD/
SCID mice in 24-hour (Fig. 7B). Administration of edaravone-pretreated stem cells partially alleviated 
such hepatic injury (Fig. 7B,C). Seven days after the treatment, edaravone-pretreated stem cells showed 
the best ameliorative effects while DEM-pretreated stem cells exhibited only minimal therapeutic effects, 
when compared to the non-stem cell injected Gal/LPS group (Fig. 7B,C). In the vehicle control groups, 
injection of either hUCMSCs or edaravone/DEM pre-treated hUCMSCs showed no significant changes 
on the liver morphology throughout the experiment (data not shown).
To quantify the human-derived cells engrafted in the NOD/SCID mice liver, the ratio between 
human gene (Down Syndrome Region Sequence) and host genome at the end of the experiment (7 
days) was determined by using quantitative real-time PCR. It was found that vehicle stem cell groups (no 
pre-treatment, edaravone or DEM pre-treated) only generated a small amount of human gene (Fig. 7D). 
Transplantation with edaravone-pretreated hUCMSCs following the Gal/LPS intoxication showed the 
highest abundance of human gene, while DEM-pretreated hUCMSCs showed significantly less human 
gene than that of non-treated hUCMSCs after Gal/LPS intoxication (Fig.  7D). These results suggested 
that administration of hUCMSCs after acute liver injury could accelerate the host hepatic regenerative 
process. Edaravone pre-treatment significantly improved the therapeutic effects and engraftment efficacy 
of stem cells while DEM pre-treatment impaired these effects. In addition, recruitment of hUCMSCs into 
the mice liver was also examined by PKH immunofluorescence (IF) and further proved that edaravone 
improved the expansion efficiency of stem cells after acute liver failure (Fig. 7E).
Transplantation of hUCMSCs improved serum biochemistry. To examine the influence of anti-
oxidant status in stem cell proliferation and apoptosis after transplantation, we quantified the number of 
PCNA+ cells or apoptotic cells (with co-staining of hCK-18) per × 40 high-powered field. It was shown 
that, when compared with untreated hUCMSCs, pre-treatment with edaravone significantly increased 
the PCNA+ cell number but reduced the apoptotic cell number, indicating a potentiated resistance of 
transplanted hUCMSCs against host liver stresses (Fig. 8A,B).
To further study the influence of edaravone or DEM on the therapeutic effects of hUCMSCs on 
Gal/LPS induced acute liver injury, changes of serum ALT and AST levels in each group of mice were 
evaluated at 1-, 3-, and 7-day post-injection of Gal/LPS challenge. One-day and 3-day after the Gal/LPS 
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Figure 5. In vitro dynamic effects of edaravone and diethyl maleate (DEM) treatments of human 
umbilical cord mesenchymal stem cells (hUCMSCs) on phosphorylated and total MAPKs (p38 MAPK 
and ERK1/2) expression after lipopolysaccharide (LPS)/H2O2 intoxication (n = 4). The protein expression 
of both p38 MAPK and ERK1/2 was measured by Western blot (a) and normalized by internal control 
β -actin (b). Quantified data were conducted by using ImageJ. LPS, LPS/H2O2 challenge; L+ E10, LPS/
H2O2 + 10 μ M edaravone; L+ E20, LPS/H2O2 + 20 μ M edaravone; L+ D, LPS/H2O2 + DEM. “*” “**” “***” 
mean significant changes (P < 0.05, 0.01, 0.001) between control and treatments, respectively; “##” “###” 
mean significant changes (P < 0.01, 0.001) between edaravone treatment group (10 μ M or 20 μ M) and LPS/
H2O2 group, respectively; “@” “@@” “@@@” mean significant change (P < 0.05, 0.01, 0.001) between DEM-
treated group and LPS/H2O2 group, respectively.
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challenge, both ALT and AST levels in the serum of all Gal/LPS-treated mice increased significantly 
as compared to those of the untreated control mice. However, transplantation of hUCMSCs signifi-
cantly reduced the serum concentrations of these liver injury indicators (Fig. 8C,D). In consistent with 
the histological results, edaravone pre-treated hUCMSCs showed stronger reducing ability of both ALT 
and AST while DEM pre-treatment significantly impaired the alleviation (Fig.  8C,D). Then the serum 
levels of pro-inflammatory cytokines, TNF-α and IL-6, were examined by ELISA assay in each group 
of mice at day 3 and day 7 post-treatment. Transplantation with hUCMSCs significantly reduced the 
pro-inflammatory secretion induced by Gal/LPS treatment at both time points, indicating an attenu-
ated status of body inflammation. Edaravone further improved the amelioration of inflammation while 
DEM treatment exacerbated it (Fig. 8E,F). At last, we measured the hepatic expressional changes of liver 
regeneration-related genes, OSM and EGF mice at day 3 and day 7 post-treatment. At day 3, treatment 
with Gal/LPS significantly induced the expression of these two genes, which was further enhanced by 
Figure 6. In vitro dynamic effects of edaravone and diethyl maleate (DEM) treatments of human 
umbilical cord mesenchymal stem cells (hUCMSCs) on Nrf2 expression and its upstream/downstream 
pathway after lipopolysaccharide (LPS)/H2O2 intoxication (n = 4). (a) The activity change of Nrf2 of 
hUCMSCs was measured by a commercial kit from nuclear protein. (b,c) The mRNA expressional change 
of NAD(P)H:quinone oxidoreductase-1 (NQO-1) and malic enzyme-1 (ME-1) measured by quantitative 
PCR. (d) After the application MAPK inhibitor PD98059 (25 μ M) and PKC inhibitor staurosporine (10 nM), 
the beneficial effects of 20 μ M edaravone on cell viability were partially abolished. (e) Silence of Keap1 
by specific siRNA significantly increased the Nrf2 activity. (f) Enhancement of Nrf2 activity by Keap1 
silence partially reversed the detrimental effects of DEM on cell viability. “*” “**” “***” mean significant 
changes (P < 0.05, 0.01, 0.001) between control and treatments, respectively; “#” “##” “###” mean significant 
changes (P < 0.05, 0.01, 0.001) between edaravone treatment group (10 μ M or 20 μ M) and LPS/H2O2 group, 
respectively; “@” “@@” mean significant change (P < 0.05, 0.01) between DEM-treated group and LPS/
H2O2 group, respectively. LPS, LPS/H2O2 challenge; Eda10, 10 μ M edaravone; Eda20, 20 μ M edaravone; PD, 
PD98059; STA, staurosporine.
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Figure 7. In vivo effects of edaravone and diethyl maleate (DEM) treatments of human umbilical cord 
mesenchymal stem cells (hUCMSCs) on their therapeutic efficacy in an acute liver failure model induced 
by D-galactosamine/LPS (Gal/LPS). (a) Edaravone treatment showed better rescuing effects on NOD/
SCID mice death than untreated and DEM-treated hUCMSCs. (b,c) Edaravone treatment showed better 
ameliorative effects on hepatic histology than untreated and DEM-treated hUCMSCs after liver failure. 
Yellow arrows indicate typical necro-inflammatory cells. (d) Edaravone increased while DEM decreased the 
expanded cell number in the host liver after transplantation. (e) Localization of hUCMSCs in the Gal/LPS-
challenged mouse liver using PKH immunofluorescnece at day 7 post-infusion. Quantified data also proved 
the finding. GL, Gal/LPS. Magnification 200x. Bar: 20 μ m. “*” “**” “***” mean significant changes (P < 0.05, 
0.01, 0.001) between indicated two groups, respectively.
www.nature.com/scientificreports/
13Scientific RepoRts | 5:11100 | DOi: 10.1038/srep11100
Figure 8. In vivo effects of edaravone and diethyl maleate (DEM) treatments of human umbilical cord 
mesenchymal stem cells (hUCMSCs) on serum markers and liver regeneration in an acute liver failure 
model induced by D-galactosamine/LPS (Gal/LPS). (a,b) Edaravone treatment promoted proliferation 
and decreased apoptosis of transplanted hUCMSCs in the murine liver. (c,d) Edaravone further improved 
the ameliorative effects of hUCMSCs on serum aminotransferases level. (e,f) Edaravone further reduced 
the production of pro-inflammatory cytokines after liver failure. (g,h) Edaravone further promoted the host 
liver regeneration after liver failure. “*” “**” “***” mean significant changes (P < 0.05, 0.01, 0.001) between 
control and treatments, respectively; “#” “##” “###” mean significant changes (P < 0.05, 0.01, 0.001) between 
edaravone treatment group (10 μ M or 20 μ M) and LPS/H2O2 group, respectively; “@” means significant 
change (P < 0.05) between DEM-treated group and LPS/H2O2 group, respectively. GL, Gal/LPS.
the transplantation with hUCMSCs. As expected, edaravone further enhanced the expression while DEM 
reduced it (Fig. 8G,H). At day 7, the expressional change of these genes was not as obvious as day 3.
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Infused hUCMSCs ameliorated host hepatic injury partly through secreting HGF. To elucidate 
the possible mechanisms of the ameliorated role of transplanted stem cells in the host liver, we firstly 
evaluated the secretion level change of HGF by cultured hUCMSCs. It was shown that naïve hUCM-
SCs secreted measurable level of HGF to the culture medium. Pre-treatment with edaravone slightly 
promoted such secretion while DEM showed opposite effects (Fig.  9A). Furthermore, we found that 
after transplantation, infused stem cells were capable of secreting HGF in the host liver. DEM treatment 
impaired such paracrine actions (Fig. 9B,C).
Discussion
Stem cell-based therapy has been recognized as a promising treating strategy of a variety of diseases, 
including liver disorders. For example, bone marrow MSCs provide protection against liver injury by 
antioxidative process, vasculature protection, hepatocyte differentiation, and trophic effects27. However, 
the efficacy of these therapies is below expectations28. One of the main reasons for this is the low survival 
ratio of transplanted stem cells at injured sites because of harsh oxidative stress and inflammatory envi-
ronment29. To counter these effects, a number of pre-treatment methods began to emerge. For example, 
it was reported that pre-treatment with antioxidant N-acetylcysteine (NAC) significantly improved cell 
survival ratio of muscle-derived stem cells (MDSCs) and cardiac function in an acute murine model of 
myocardial infarction14. A recent study also found that treatment with melatonin, a common antioxidant, 
further improved adipose-derived mesenchymal stem cell (ADSC) therapy for acute interstitial cystitis 
in rat30. Thus, enhancement of endogenous antioxidant level of stem cells before transplantation seems 
to be a strategy to improve the therapeutic efficacy.
We have previously identified that hUCMSCs, which are easily accessible and multipotent, exhibited 
evident repairing effects on an acute liver failure murine model induced by Gal/LPS15. Although these 
hUCMSCs and trans-differentiated i-Heps rescued mice with improved hepatic functions, the repair 
process remains limited. To increase the repair efficacy, in the current study, we firstly used edaravone 
as antioxidant and DEM, a nontoxic chemical that binds to GSH and inactivates it, to reduce antioxidant 
levels31, as pro-oxidant to examine the dynamic changes of cellular endogenous antioxidant level, viability, 
and apoptosis. From 24-hour post-treatment, hUCMSCs started to show significant loss of viability, with 
increased ROS production and cellular apoptosis. Edaravone significantly counteracted such effects while 
DEM further exacerbated them, including the regulation of antioxidant enzymes and apoptotic genes. 
This result is consistent with other studies using NAC or melatonin14,30. It was extensively studied that 
MAPK and PKC pathways could directly modulate the transcriptional activity of Nrf2, which plays anti-
oxidant roles by controlling the transcription of downstream genes32,33. We also found that the beneficial 
effects of edaravone on hUCMSCs were through decrease of phosphorylated p38 MAPK and ERK1/2, 
Figure 9. Assessment of secretion and expression of human hepatocyte growth factor (HGF) by human 
umbilical cord mesenchymal stem cells (hUCMSCs) in vitro and in vivo. (a) In vitro measurements of 
HGF secretion by hUCMSCs with or without pre-treatment by edaravone or diethyl maleate (DEM). (b,c) 
Representative in vivo image of HGF-positive cells by infused hUCMSCs in the host mouse liver at day 7 
post challenge. Eda10, 10 μ M edaravone; Eda20, 20 μ M edaravone; GL, D-galactosamine/LPS. “*” “***” mean 
significant changes (P < 0.05, 0.001) between indicated two groups, respectively. Bar: 50 μ m.
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as well as increase of Nrf2 activity and its downstream antioxidant enzyme expression (Figs  5 and 6). 
Application of MAPK inhibitor PD98059 or PKC inhibitor staurosporine reversed the improvement by 
edaravone. Silence of Nrf2 inhibitory protein – Keap1 partially abolished the detrimental effects of DEM. 
These results confirmed that the modulation of stem cell endogenous antioxidant level was, at least partly, 
through the MAPK-PKC-Nrf2 pathway. This is confirmed by a very recent study showing that dynamic 
changes in intracellular ROS levels regulate stem cell homeostasis through Nrf2-dependent signaling34. 
It should be noted that in the current study, expression of antioxidant enzymes (CAT, SOD1, NQO-1 
and ME-1) and Nrf2 activity were down-regulated by oxidant treatment, which was in line with several 
recent studies in stem cells and hepatocytes35–37. Some other reports, however, found that antioxidant 
genes are increased to survive when cells are exposed to oxidative stress inducers30,38,39. This difference 
might be attributed to the defensive nature of human MSCs to oxidative stress through expressing high 
basal level of active forms of CAT, glutathione peroxidase (GPx), and SOD, which confers the resistance 
against acute ROS-mediated cellular damage40. Addition of toxin or oxidant may impair this defense wall 
to maintain the relatively low level of antioxidant enzymes and Nrf2 activity, resulting in the oxidative 
stress status of the stem cells.
In line with the in vitro findings, when compared with untreated hUCMSCs, edaravone pre-treated 
stem cells exhibited improved therapeutic properties, including enhanced survival ratio of the mice, 
improved hepatic histology, reduced serum aminotransferases/cytokines and promoted liver regenera-
tion (Figs 7 and 8). This can be from increased transplanted stem cell number, which is probably from 
induced cell proliferation and inhibited apoptosis by the pre-treatment with edaravone. In contrast, 
DEM-treated hUCMSCs showed minimal therapeutic effects on acute liver failure. These results strongly 
suggested that the antioxidant status of hUCMSCs before transplantation is vital for the functional tissue 
repair of acute liver failure14.
Indeed, there are several limitations of the current study. Firstly, we only investigated the involvement 
of MAPK, PKC and Nrf2 in the regulation of stem cell antioxidant status. Functions of other oxidative 
stress-related pathways, such as PI3K/Akt and FoxO/TXNIP need further studies. Secondly, mechanisms 
that influence the enhanced repairing efficacy of stem cell after transplantation are only partly examined. 
We proved that increased number of transplanted hUCMSCs secreted more HGF to promote the recov-
ery of adjacent host liver cells and this action was also influenced by the antioxidant and pro-oxidant 
treatments (Fig.  9), which was consistent with previous reports41,42. Thirdly, regardless of the fact that 
MSCs are proven with minimal immunogenicity and low tumorigenesis43, the safety of drug-treated stem 
cell transplantation needs long-term observation in animal models and clinical trials. In a long-term 
approach in NOD/SCID mice, the safe and efficient use of MSCs by injection not revealed side effect44.
ROS are increasingly recognized as important signaling molecules involved in gene regulation of stem 
cells45. Since oxidative stress, inflammation, and necro-apoptosis are typical consequences of acute liver 
failure which holds high possibility to cause death46, transplantation with enhanced anti-oxidative ability 
stem cells may significantly improve the therapeutic efficacy in clinical trials. Thus, reducing the in vitro 
culture duration15 and maintaining relatively high antioxidant endogenous level of isolated stem cells 
(e.g. by clinically proven drug edaravone) before transplantation are possible strategies for future regen-
erative medicine applications. Furthermore, this study (1) provided useful information of the dynamic 
cellular changes at different time points after in vitro oxidative/inflammatory stress induction, which 
will assist future stem cell handling in both basic study and clinical trials; and (2) implied a new potent 
and widely used clinical drug, edaravone, as an useful antioxidant treating agent in stem cell preparation 
before transplantation.
References
1. Keeffe E. B. Liver transplantation: current status and novel approaches to liver replacement. Gastroenterology 120, 749–762 
(2001).
2. van Poll D. et al. Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and 
in vivo. Hepatology 47, 1634–1643 (2008).
3. Rountree C. B., Mishra L. & Willenbring H. Stem cells in liver diseases and cancer: recent advances on the path to new therapies. 
Hepatology 55, 298–306 (2012).
4. Tan C. Y. et al. Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. 
Stem Cell Res Ther 5, 76 (2014).
5. Wesson R. N. & Cameron A. M. Stem cells in acute liver failure. Adv Surg 45, 117–130 (2011).
6. Levine P. et al. Molecular mechanisms of stem cell therapy in alcoholic liver disease. Dig Liver Dis 46, 391–397 (2014).
7. Winkler S. et al. Human mesenchymal stem cells towards non-alcoholic steatohepatitis in an immunodeficient mouse model. 
Exp Cell Res 326, 230–239 (2014).
8. Zhang Z. & Wang F. S. Stem cell therapies for liver failure and cirrhosis. J Hepatol 59, 183–185 (2013).
9. Li Z., He C., Xiao J. & Chen Z. Treating end-stage liver diseases with mesenchymal stem cells: an oak is not felled at one stroke. 
OA Tissue Engin 1, 3 (2013).
10. Ryu K. H. et al. Tonsil-derived mesenchymal stem cells alleviate concanavalin A-induced acute liver injury. Exp Cell Res 326, 
143–154 (2014).
11. Yuasa M. et al. Herpes simplex virus type 2 fulminant hepatitis after umbilical cord blood transplantation for acute myeloid 
leukemia. Rinsho Ketsueki 55, 682–686 (2014).
12. Dernbach E. et al. Antioxidative stress-associated genes in circulating progenitor cells: evidence for enhanced resistance against 
oxidative stress. Blood 104, 3591–3597 (2004).
13. He T. et al. Human endothelial progenitor cells tolerate oxidative stress due to intrinsically high expression of manganese 
superoxide dismutase. Arterioscler Thromb Vasc Biol 24, 2021–2027 (2004).
www.nature.com/scientificreports/
1 6Scientific RepoRts | 5:11100 | DOi: 10.1038/srep11100
14. Drowley L. et al. Cellular antioxidant levels influence muscle stem cell therapy. Mol Ther 18, 1865–1873 (2010).
15. Zhou R. et al. Human umbilical cord mesenchymal stem cells and derived hepatocyte-like cells exhibit similar therapeutic effects 
on an acute liver failure mouse model. PLoS One 9, e104392 (2014).
16. Xiao J. et al. Tumor necrosis factor-alpha gene from mandarin fish, Siniperca chuatsi: molecular cloning, cytotoxicity analysis 
and expression profile. Mol Immunol 44, 3615–3622 (2007).
17. Xiao J. et al. Lycium barbarum polysaccharide attenuates alcoholic cellular injury through TXNIP-NLRP3 inflammasome 
pathway. Int J Biol Macromol 69, 73–78 (2014).
18. Bustin S. A. et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin 
Chem 55, 611–622 (2009).
19. Xiao J. et al. Garlic-derived S-allylmercaptocysteine is a hepato-protective agent in non-alcoholic fatty liver disease in vivo animal 
model. Eur J Nutr 52, 179–191 (2013).
20. Liong E. C., Xiao J., Lau T. Y., Nanji A. A. & Tipoe G. L. Cyclooxygenase inhibitors protect D-galactosamine/lipopolysaccharide 
induced acute hepatic injury in experimental mice model. Food Chem Toxicol 50, 861–866 (2012).
21. Song P. et al. Human genome-specific real-time PCR method for sensitive detection and reproducible quantitation of human 
cells in mice. Stem Cell Rev 8, 1155–1162 (2012).
22. Li P. et al. PKH26 can transfer to host cells in vitro and vivo. Stem Cells Dev 22, 340–344 (2013).
23. Park M. et al. Tonsil-derived Mesenchymal Stem Cells Ameliorate CCl4-induced Liver Fibrosis in Mice via Autophagy Activation. 
Sci Rep 5, 8616 (2015).
24. Jones D. P. Redefining oxidative stress. Antioxid Redox Signal 8, 1865–1879 (2006).
25. Panigrahi G. K. et al. Hepatic transcriptional analysis in rats treated with Cassia occidentalis seed: Involvement of oxidative stress 
and impairment in xenobiotic metabolism as a putative mechanism of toxicity. Toxicol Lett 229, 273–283 (2014).
26. Itoh K., Tong K. I. & Yamamoto M. Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to 
electrophiles. Free Radic Biol Med 36, 1208–1213 (2004).
27. Francois S. et al. Human mesenchymal stem cells provide protection against radiation-induced liver injury by antioxidative 
process, vasculature protection, hepatocyte differentiation, and trophic effects. BioMed Res Int 2013, 151679 (2013).
28. Bhatia S. N., Underhill G. H., Zaret K. S. & Fox I. J. Cell and tissue engineering for liver disease. Sci Transl Med 6, 245sr242 
(2014).
29. Chang W. et al. Anti-death strategies against oxidative stress in grafted mesenchymal stem cells. Histol Histopathol 28, 1529–1536 
(2013).
30. Chen Y. T. et al. Melatonin treatment further improves adipose-derived mesenchymal stem cell therapy for acute interstitial 
cystitis in rat. J Pineal Res 57, 248–261 (2014).
31. Oshima H. et al. Differential myocardial infarct repair with muscle stem cells compared to myoblasts. Mol Ther 12, 1130–1141 
(2005).
32. Kim Y. S., Pi S. H., Lee Y. M., Lee S. I. & Kim E. C. The anti-inflammatory role of heme oxygenase-1 in lipopolysaccharide and 
cytokine-stimulated inducible nitric oxide synthase and nitric oxide production in human periodontal ligament cells. J Periodontol 
80, 2045–2055 (2009).
33. Zipper L. M. & Mulcahy R. T. Erk activation is required for Nrf2 nuclear localization during pyrrolidine dithiocarbamate 
induction of glutamate cysteine ligase modulatory gene expression in HepG2 cells. Toxicol Sci 73, 124–134 (2003).
34. Paul M. K. et al. Dynamic Changes in Intracellular ROS Levels Regulate Airway Basal Stem Cell Homeostasis through Nrf2-
Dependent Notch Signaling. Cell Stem Cell 15, 199–214 (2014).
35. Ebert R. et al. Selenium supplementation restores the antioxidative capacity and prevents cell damage in bone marrow stromal 
cells in vitro. Stem Cells 24, 1226–1235 (2006).
36. Wang X. Q. et al. Decreased SIRT3 in aged human mesenchymal stromal/stem cells increases cellular susceptibility to oxidative 
stress. J Cell Mol Med 18, 2298–2310 (2014).
37. Kim I. D. & Ha B. J. The effects of paeoniflorin on LPS-induced liver inflammatory reactions. Arch Pharm Res 33, 959–966 
(2010).
38. Loseva P. et al. Extracellular DNA oxidation stimulates activation of NRF2 and reduces the production of ROS in human 
mesenchymal stem cells. Expert Opin Biol Ther 12 Suppl 1, S85–97 (2012).
39. Huang Z., Li J., Zhang S. & Zhang X. Inorganic arsenic modulates the expression of selenoproteins in mouse embryonic stem 
cell. Toxicol Lett 187, 69–76 (2009).
40. Valle-Prieto A. & Conget P. A. Human mesenchymal stem cells efficiently manage oxidative stress. Stem Cell Dev 19, 1885–1893 
(2010).
41. Bai L. et al. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat 
Neurosci 15, 862–870 (2012).
42. Song Y. S. et al. Mesenchymal stem cells overexpressing hepatocyte growth factor (HGF) inhibit collagen deposit and improve 
bladder function in rat model of bladder outlet obstruction. Cell Transplant 21, 1641–1650 (2012).
43. Uccelli A., Moretta L. & Pistoia V. Mesenchymal stem cells in health and disease. Nature Rev Immunol 8, 726–736 (2008).
44. Francois S., Usunier B., Douay L., Benderitter M. & Chapel A. Long-Term Quantitative Biodistribution and Side Effects of 
Human Mesenchymal Stem Cells (hMSCs) Engraftment in NOD/SCID Mice following Irradiation. Stem Cell Int 2014, 939275 
(2014).
45. Pervaiz S., Taneja R. & Ghaffari S. Oxidative stress regulation of stem and progenitor cells. Antioxid Redox Signal 11, 2777–2789 
(2009).
46. Bernal W. & Wendon J. Acute liver failure. N Engl J Med 369, 2525–2534 (2013).
Acknowledgments
This work was supported by National Natural Science Foundation of China (Grant No. 31300813 and 
81370971, http://www.nsfc.gov.cn/), The Medical Key Discipline Project of Shenzhen (No. 201161) and 
Guangdong Natural Science Funds for Distinguished Young Scholar (S2013050013880). The authors 
declare no conflict of interest.
Author Contributions
J.X., F.X., Z.Y.C. and Y.L., designed the study. Z.W., J.X., G.Z. and X.W., performed the experiments. Z.W., 
J.X., G.Z., F.X., G.L.T., C.H. and Y.L., analyzed the data. J.X., F.X., G.L.T., Z.Y.C. and Y.L., wrote and edited 
the manuscript. All authors reviewed and approved the manuscript.
www.nature.com/scientificreports/
17Scientific RepoRts | 5:11100 | DOi: 10.1038/srep11100
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Zeng, W. et al. Antioxidant treatment enhances human mesenchymal stem 
cell anti-stress ability and therapeutic efficacy in an acute liver failure model. Sci. Rep. 5, 11100; doi: 
10.1038/srep11100 (2015).
This work is licensed under a Creative Commons Attribution 4.0 International License. The 
images or other third party material in this article are included in the article’s Creative Com-
mons license, unless indicated otherwise in the credit line; if the material is not included under the 
Creative Commons license, users will need to obtain permission from the license holder to reproduce 
the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
